摘要
目的观察胸腺素α1对急性白血病并发肺部感染的疗效。方法将38例急性白血病并发肺部感染患者随机分为治疗组21例和对照组17例。两组均给予抗生素(第3代头孢菌素、碳青酶烯类或万古霉素)治疗。治疗组同时给予胸腺素α11.6 mg皮下注射,qd。共2周。直接免疫荧光技术检测治疗前后外周血T淋巴细胞亚群(CD3+、CD4+、CD8+)百分率,酶联免疫吸附法测定白细胞介素2(IL-2)、IL-6和α干扰素(INF-α),观察临床疗效。结果治疗组治疗后IL-2升高,CD3+、CD4+、CD4+/CD8+百分率均显著提高(P<0.05或P<0.01),INF-α降低(P<0.01);对照组治疗后INF-α降低(P<0.05),CD4+明显提高(P<0.01)。治疗组治疗后CD4+百分率和CD4+/CD8+明显高于对照组(P<0.01,P<0.05)。治疗组总有效率(90.48%)明显高于对照组(70.59%)(P<0.05)。结论胸腺素α1可提高白血病患者机体免疫功能,促进机体产生淋巴因子,改善感染患者细胞因子和细胞免疫失衡,有助于控制白血病并发肺部感染。
Objective To investigate the efficacy of thymic peptide α1 on secondary pulmonary infection of acute leukemia. Methods Thirty-eight patients with secondary pulmonary infection of acute leukemia were divided into two groups, the control group and thymic peptide α1 combined with antibiotic treatment group. Both groups were treated with antibiotics for two weeks, while the therapeutic group was s.c. treated with 1.6 mg thymic peptide α1 as well. The percentage of T lymphocyte subsets（ CD3^＋ , CD4^＋, CD8^＋ ） in peripheral blood was detected by direct immunofluorescence, and IL-2, IL-6 and INF-α were analyzed by enzyme linked immunosorbent assay. The effect was carefully observed. Results In the thymic-peptide α1- treatment group, IL-2 ,as well as the percentages of CD3^＋ ,CD4^＋ ,and CD8^＋ increased significantly（ P 〈 0.05 and P 〈 0.01 ） and INF-α was lowered （P 〈 0.01 ） after treatment. INF-α of the control group was lowered （P 〈 0.05 ） while CD4^＋ significantly increased（P 〈 0.01 ）after treatment. Total effective rates were 90.4% and 70.5% for the treatment group and the control one, respectively （ P 〈 0.05 ）. Conclusion Thymic peptide promotes immune function of the infected patiens, by enhancing production of cytokines and improving the unbalance of cellular immunity.
出处
《医药导报》
CAS
2008年第11期1343-1345,共3页
Herald of Medicine
关键词
胸腺素Α1
白血病
急性
感染
肺部
免疫功能
Thymic Peptide α1
Leukemia, acute
Infection, pulmonary
Immunity efficacy
